title: Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases.
authors.forename: C R
authors.initials: CR
authors.lastname: Chalmers
authors.forename: D J
authors.initials: DJ
authors.lastname: Wilson
authors.forename: J
authors.initials: J
authors.lastname: Ward
authors.forename: P J
authors.initials: PJ
authors.lastname: Robinson
authors.forename: G J
authors.initials: GJ
authors.lastname: Toogood
authors.forename: M A
authors.initials: MA
authors.lastname: Hull
mesh_terms: D015179:Colorectal Neoplasms / Q000097:blood / Q000473:pathology*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D043169:Endostatins / Q000097:blood; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000097:blood / Q000098:blood supply* / Q000556:secondary*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D013450:Sulfones / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D043169:Endostatins; D007783:Lactones; D013450:Sulfones; D042461:Vascular Endothelial Growth Factor A; C116926:rofecoxib